Clinical Pharmacology and Therapeutics
Clinical Pharmacology and Therapeutics
5 years ago

Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers

Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers
S. J. Kim, E. S. Oh, M. S. Park, K. H. Kim, C. Choi, C. O. Kim, Y. N. Kim
What is known and objective Evogliptin (DA-1229), a novel dipeptidyl peptidase (DPP)-4 inhibitor with high potency and selectivity, was approved in Korea for the treatment of type 2 diabetes. Preclinical studies suggest that it is metabolized by cytochrome (CYP) P450 isozymes. Based on these findings, a clinical study was designed to investigate the pharmacokinetic (PK) interaction of evogliptin with a CYP inhibitor, clarithromycin. Methods An open-label, two-phase, crossover study was conducted with 12 healthy subjects. On day 1, a single dose of evogliptin 5 mg was administered alone to assess the reference PK profile of evogliptin. On day 10, after a 2-day pretreatment with clarithromycin, evogliptin 5 mg was administered again to evaluate the effect of CYP inhibition on the PK profile of evogliptin. Administration of clarithromycin continued until day 14. Blood sampling in the reference and test phases was performed until 96 and 168 hours after dosing, respectively for PK assays. Results Eleven of the 12 subjects completed the study, and their data were analysed. In the presence of clarithromycin, exposure to evogliptin increased without any serious adverse events and the geometric mean peak plasma concentration (Cmax) and area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-∞) of evogliptin increased by 116.5% and 89.6%, respectively. What is new and conclusion Administration of clarithromycin significantly increased exposure to evogliptin in healthy subjects. A clinical study was designed to investigate the pharmacokinetic (PK) interaction of evogliptin with a CYP inhibitor, clarithromycin. In 12 healthy subjects, a single dose of evogliptin 5 mg was administered alone or after a 2-day pretreatment with clarithromycin to assess the PK profile of evogliptin. In the presence of clarithromycin, exposure to evogliptin increased without any serious adverse events and the Cmax and AUC0-∞ of evogliptin increased by 116.5% and 89.6% respectively.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1111/jcpt.12604

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.